Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(Incorporated in Bermuda with limited liability)
(Stock Code: 00512)

VOLUNTARY ANNOUNCEMENT

TREPROSTINIL INJECTION (20ML: 50MG) IS GRANTED A DRUG REGISTRATION CERTIFICATE

This announcement is made by the board of directors (the "**Board**") of Grand Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board is pleased to announce that a new specification (20ML: 50MG) of the Group's Treprostinil Injection for the treatment of pulmonary arterial hypertension ("**PAH**", WHO classification 1) has been granted a Drug Registration Certificate by the National Medical Products Administration of the People's Republic of China (NMPA) recently. The 20ml:20mg specification of this product was approved for commercialization in March 2023. The product is included in the medical insurance catalogue. The two specifications will help clinicians provide more precise treatment plans based on the patient's condition. This is a significant breakthrough for the Group in the direction of rare diseases in the field of cerebro-cardiovascular emergency.

In November 2024, the Group entered into an equity investment agreement and a product cooperation agreement with Shanghai ForeFront Pharmaceutical Co., Ltd. ("**ForeFront Pharma**"). According to the agreement, upon the satisfaction of relevant conditions, the Group will subscribe for approximately 14.42% of ForeFront Pharma's equity, and obtain the exclusive commercialization rights in Greater China (Mainland China, Hong Kong SAR of China, Macao SAR of China, and Taiwan Region of China) for Treprostinil Inhalation Preparations for the treatment of PAH, the exclusive global commercialization rights (excluding the UAE, Ireland, and Russia) for Treprostinil Injection and the exclusive global commercialization rights (excluding Mainland China) for its APIs, and the exclusive global commercialization rights for Sapropterin Tablet for the treatment of phenylketonuria and the exclusive overseas commercialization rights for its API; meanwhile, the Group will also enjoy the priority negotiation rights for the exclusive overseas commercialization rights for Treprostinil Inhalation Preparations, exclusive global commercialization rights for other pipeline products, and the transfer of Marketing Authorization Holder (MAH) for related

products of ForeFront Pharma, and a series of priority rights for equity transactions of ForeFront Pharma. The Group will comprehensively build a global sales network in the field of pharmaceutical technology, gradually promote the internationalization of pharmaceutical technology, and ultimately achieve a comprehensive transformation into a large-scale comprehensive multinational pharmaceutical company.

Pulmonary arterial hypertension (PAH) refers to a clinical and pathophysiological syndrome characterized by structural or functional changes in the pulmonary vasculature due to a variety of heterogeneous diseases (etiologies) and different pathogenic mechanisms, leading to elevated pulmonary vascular resistance and pulmonary artery pressure. It can progress to right heart failure and even death. According to the WHO classification, PAH is a type 1 subtype of pulmonary hypertension, characterized by primary lesions in the distal pulmonary arteries. Epidemiological data on PAH from multiple international registries show that the incidence of PAH in adults is approximately 2.4 per million person-years, and a prevalence of approximately 15 per million, making it a relatively rare cardiovascular disease. PAH has high mortality and disability rates. In the era of traditional treatment lacking targeted drugs, PAH has a poor prognosis, with a median survival of only 2.8 years. A third-party report shows that the global PAH market size will be approximately USD8.06 billion in 2024, of which prostacyclins will account for 45% of the market share. It is estimated that by 2034, the global PAH market size will reach approximately USD13.5 billion, with a compound annual growth rate of 5.3%. The annual compound growth rate in the Asia-Pacific region is expected to reach 13.3%, indicating huge market prospects.

Treprostinil is an artificial synthetic prostacyclin analog that promotes vasodilation and inhibits platelet aggregation, thereby treating the symptoms of PAH. Multiple clinical studies have confirmed the long-term efficacy and safety of treprostinil. One-year and four-year survival rates with monotherapy are 88% and 70%, respectively, significantly improving patient prognosis. Treprostinil Injection is now a first-line medication for the treatment of PAH in clinical practice and a basic medication of targeted drug combination therapy. It is also the only subcutaneous and intravenous dosing prostacyclin approved for the treatment of PAH in China. The approval of the Group’s Treprostinil Injection successfully changes the single product monopoly of this product in the domestic market, and is expected to further reduce the medical burden on PAH patients.

Cerebro-cardiovascular emergency segment is one of the key strategic plans of the Group in the field of pharmaceutical technology. listed as “national essential drug production base”, “emergency medicines manufacturer for national ready reserve” and “national centralized production base and construction unit for minority-variety medicines (drugs in short supply)”, the Group have nearly 30 varieties in cerebro-cardiovascular emergency segment, 14 of which are included in the national emergency drugs catalogue, and 16 of which are included in the shortage drugs catalogue, ranking the top in the industry in terms of product pipeline. Currently, there are more than 20 products under research in the cerebro-cardiovascular emergency segment. In terms of rare diseases, in addition to the new specification of Treprostinil Injection that newly commercialized, Carglumic Acid Dispersible Tablet, for the treatment of hyperammonemia in adults or children caused by N-acetylglutamate synthetase (NAGS) deficiency, isovaleric acidemia (IVA), methylmalonic acidemia (MMA), or propionic acidemia (PA), was approved for commercialization in 2023; Pasireotide Diaspartate Injection, for the treatment of Cushing’s disease in adults with pituitary surgery who are not candidates or whose surgery has not been successful, was approved for commercialization in May 2025. A commercialization application has been submitted for Vigabatrin Powder for Oral Solution for

the treatment of West syndrome; the research and development of several other rare disease drugs is also progressing smoothly. Rare diseases are one of the greatest medical challenges facing humanity. Compared to other diseases, clinical diagnosis and treatment for patients with rare diseases are more complex and difficult. Currently, only 5% of rare diseases worldwide have effective treatments, while treatment is expensive. Most rare disease patients still face the dilemma of "no available drugs" or "expensive medication costs". To meet the clinical needs of rare diseases, respond to the call of the government and society, and fulfill the social responsibility of pharmaceutical companies, the Group will continue to increase its research and development of rare disease drugs, bringing more safe and effective treatment options to rare disease patients and continuously contributing to alleviating the burden on patients.

The Group always puts focus on the R&D of innovative products and advanced technologies. Adhering to a patient-centered and innovation-driven approach, the Group will continue to increase its investment in world-class innovative products and advanced technologies to meet unmet clinical needs and enrich its product pipeline and improve supply chain. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. In this way, the Group can make full use of its industrial advantages and R&D capabilities, to accelerate the commercialization process for innovative products and provide patients with more advanced and diverse treatment options globally.

Warning:

The production, sales and contributed profit of aforementioned product is subject to various factors such as market changes with uncertainty. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

Note: The English transliteration of the Chinese name(s) in this announcement is included for information purpose only, and should not be regarded as the official English name(s) of such Chinese name(s).

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 23 September 2025

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Mr. Yang Guang and Ms. Lam Chit Yee Jessica, and four independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Xing Li Na, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*